IPM Take
The sharp point is that familial hypercholesterolaemia is preventable risk hiding in plain sight. Europe already has evidence, advocacy and policy momentum, but implementation still depends on whether countries can build practical screening routes for children and families. PERFECTO matters because it turns inherited lipid detection into a delivery question: who is screened, how families are informed, how primary care is involved and whether positive results lead to lifelong prevention rather than a one-off diagnosis.
Executive Summary
On 27 April 2026, the European Public Health Alliance highlighted the closing event of the EU co-funded PERFECTO project, focused on paediatric screening for familial hypercholesterolaemia and other inherited lipid disorders. The article states that inherited lipid disorders, including familial hypercholesterolaemia, homozygous familial hypercholesterolaemia, elevated lipoprotein(a) and familial chylomicronaemia syndrome, remain underdiagnosed drivers of premature cardiovascular disease. EPHA notes that FH alone affects an estimated 2 million adults and 500,000 children across Europe, with most remaining undiagnosed.
Why it matters
- Policymakers: Need to decide whether inherited lipid screening becomes part of national cardiovascular prevention strategies, not only a specialist or advocacy issue.
- Public authorities: Should prepare practical screening routes, family communication models, cascade pathways and links to lifelong prevention.
- Patients / advocates: Can use PERFECTO to push for earlier detection, family-centred counselling and equitable screening access across countries.
Previously, inherited lipid disorders were often managed after a family history, an adult cardiovascular event or specialist referral. That misses the prevention window, especially for children who could benefit from early identification and risk management.
What has changed is the attempt to translate paediatric FH screening recommendations into practical implementation tools. PERFECTO focuses not only on the test itself, but also on the social, behavioural and policy determinants of uptake. The project developed approaches including FH ambassador training and a personalised communication model for families, with the aim of supporting national screening implementation.
The affected population includes children, families with inherited lipid risk and adults who may be identified through family or cascade screening. The implementation issue is not only laboratory detection. It is whether families understand the result, whether primary care and paediatric pathways know what to do next, and whether diagnosis connects to long-term prevention.
For IPM, the message is direct: cardiovascular prevention needs to find inherited risk before the first event. If Europe cannot scale FH screening when the biomarker, treatment and prevention logic are clear, it will struggle with more complex personalised prevention models.
